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A genome-wide study of panic disorder suggests the
amiloride-sensitive cation channel 1 as a candidate
gene
Noomi Gregersen*,1,2,10, Hans A Dahl3,4,10, Henriette N Buttenschøn1, Mette Nyegaard2,5, Anne Hedemand2,
Thomas D Als1,6, August G Wang7, Sofus Joensen8, David PD Woldbye9, Pernille Koefoed9, Ann S Kristensen1,
Torben A Kruse4, Anders D Børglum1,2 and Ole Mors1
Panic disorder (PD) is a mental disorder with recurrent panic attacks that occur spontaneously and are not associated to any
particular object or situation. There is no consensus on what causes PD. However, it is recognized that PD is influenced by
environmental factors, as well as genetic factors. Despite a significant hereditary component, genetic studies have only been
modestly successful in identifying genes of importance for the development of PD. In this study, we conducted a genome-wide
scan using microsatellite markers and PD patients and control individuals from the isolated population of the Faroe Islands.
Subsequently, we conducted a fine mapping, which revealed the amiloride-sensitive cation channel 1 (ACCN1) located on
chromosome 17q11.2-q12 as a potential candidate gene for PD. The further analyses of the ACCN1 gene using single-
nucleotide polymorphisms (SNPs) revealed significant association with PD in an extended Faroese case–control sample.
However, analyses of a larger independent Danish case–control sample yielded no substantial significant association. This
suggests that the possible risk alleles associated in the isolated population are not those involved in the development of
PD in a larger outbred population.
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INTRODUCTION
Panic disorder (PD) is a common mental disorder in society.1,2 It is
characterized by recurrent, unprovoked and unpredictable panic
attacks, followed by concern of subsequent attacks, resulting in a
strong social and functional inhibition.3,4 Estimates from family and
twin studies ascribe a genetic contribution of approximately 40% to
the disease etiology of the disorder.5–8 However, the mechanism
underlying PD is still unknown and presumably involves numerous
susceptibility genes with major and/or minor effects.9,10 Furthermore,
the possibility of allelic heterogeneity, which most likely will reduce the
power of performed studies to detect associated genes, exists. In this
context, isolated populations are considered advantageous, as they
possess highly beneficial features for diminishing genetic and allelic
heterogeneity.11–13 In the present study, we use the isolated population
of the Faroe Islands to search for susceptibility genes for PD. The
population history of this isolate in context of genetics has previously
been described.14,15 The isolate has formerly been used to locate
chromosomal regions associated with other complex disorders,16,17
which has lead to identification of genes for schizophrenia and bipolar
disorder in larger outbred populations.18–20
We present the results from a three-stage genetic investigation of PD
(Figure 1). First, we conducted a genome-wide scan on 13 distantly
related patients with PD and 43 control individuals from the Faroe
Islands. Second, we performed a fine mapping of the chromosome
regions observed to be significantly associated with PD, using the same
sample as in the genome-wide scan. In this paper, we only report the
results from the chromosome 17q11.2-q12 region. Third, the amilor-
ide-sensitive cation channel 1 (ACCN1) gene was analysed for associa-
tion with PD in an extended Faroese case–control sample and in an
outbred Danish case–control sample.
MATERIALS AND METHODS
Subjects and clinical assessment
The Faroese sample. Thirteen patients with PD and 43 control
individuals were included in the genome-wide scan. Recently, additional
18 patients and 119 control individuals were recruited to the Genetic
Biobank of the Faroe Islands. All patients were interviewed using the
Present State Examination.21 The inclusion criteria were PD with or
without agoraphobia, according to the ICD-10 diagnostic criteria.3 The
control individuals were evaluated to be healthy and were matched to
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the cases by ethnicity. A detailed description of the sample has been
described in Wang et al.22 The extended Faroese sample consisted of 31
PD patients and 162 healthy control individuals.
The Danish sample. The Danish sample consisted of 243 patients
with PD and 645 healthy control individuals. The sample was collected
from two Danish cohorts, one in the area of Copenhagen23 and the
other in Jutland.24 The patients were diagnosed with PD with or
without agoraphobia, according to the ICD-10 diagnostic criteria.3 All
the patients and controls were of Danish Caucasian origin.
Genotyping
Stage 1: The genome-wide scan. Thirteen patients with PD and 43
control individuals from the Faroe Islands were genotyped, using
approximately 500 microsatellite markers with an average inter-
marker distance of 5 cM (range 0–14 cM). Primer sequences were
obtained from the Human Genome Database (primer sequences are
available on request). DNA fragments were amplified using standard
PCR conditions in single or multiplex reactions in a concentration of
6 ng/ml DNA. The PCR fragments were analysed on the ABI 377
genetic analyser (Applied Biosystems, Foster City, CA, USA) and the
alleles were analysed using the Genemapper software version 3.7
(Applied Biosystems).
Several chromosomal regions (4p16.1, 17q11.2-q12 and 19p13.2)
showed significant association in the genome-wide scan. These regions
were submitted to further analyses in order to verify the observation
and to further delineate the identical by descended (IBD) status of
the regions.
Stage 2: The 17q11.2-q12 region. Given the results, we have, in the
present study, chosen to focus on the results from chromosome 17. To
verify the finding and to further delineate the IBD status of the
17q11.2-q12 region, the marker density was increased from 20 to 42
microsatellite markers (29 in the 17q11.2-q12 region), including the
5-HTTLPR repeat in the promoter region of the serotonin transporter
(SLC6A4) gene. The study sample and analytic procedures were the
same as in the genome-wide scan. Subsequently, the promoter region
of the ACCN1 gene was sequenced in 14 individuals using the ABI Big
Dye Terminator 3.1 kit (Applied Biosystems). The sequencing revealed
seven single-nucleotide polymorphisms (SNPs; rs28936, rs28935,
rs28933, rs62068265, rs9916605, rs7214382 and rs2228990), which
were genotyped in the complete sample from the genome-wide scan,
using the SNaPshot protocol from Applied Biosystems and analysed
on an ABI 377 genetic analyser (Applied Biosystems).
Stage 3: Amiloride-sensitive cation channel 1 (ACCN1). A bioinfor-
matic search of the chromosome segment comprising the 17q11.2-q12
region suggested the ACCN1 gene as the most interesting gene, as the
acid-sensing ion channels (ASICs) may be involved in anxiety-related
pathways.25–27 The ACCN1 gene comprises a genomic region of
approximately 1.1 Mb and contains 10 coding exons. Accor-
ding to HapMap (http://hapmap.ncbi.nlm.nih.gov/), approximately
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Figure 1 An overview of the study design: in stage 1, we conducted a genome-wide scan, which detected significant association between PD and a two-
marker segment (D17S1294–D17S1293) on chromosome 17. In stage 2, we followed up on 17q11.2-q12, which revealed significant association between
PD and several markers (D17S1540, D17S1293 and D17S1842) within this region and suggested ACCN1 as a possible candidate gene. In stage 3, we
analysed ACCN1 for association with PD, using tag-SNPs.
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500 tag-SNPs are required to capture the genetic variation of this gene.
However, we selected 55 tag-SNPs, covering exons, exon–intron
boundaries, and 3¢and 5¢ flanking regions, on the basis of the publicly
available genotype data from the Centre d¢Etude du Polymorphisme
Humain (CEPH) trios (http://www.cephb.fr/en/cephdb/), available in
the HapMap project dataset (phase II data freeze, assembly NCBI b36,
dbSNP b126). The tagging procedure was performed in Haploview,
version 3.32.28 Two SNPs (rs28936 and rs62068265) were specifically
selected to be included due to our positive findings in stage 2, whereas
rs28935 was tagged by rs8066566 (D¢¼1, r2¼1). The SNPs were
genotyped in the extended Faroese sample, and additionally, in the
Danish sample. The genotyping was performed using the Sequenom
platform as described by Nyegaard et al.20 One of the specifically
selected SNPs (rs28936) failed to be genotyped. Rs28936 is in very
high linkage disequilibrium (LD) with rs28933 (D¢¼1, r2¼0.91),
which subsequently was analysed using allele-specific hybridization
in the LightCycler 480 System (Roche Applied Science, Mannheim,
Germany). Primers for rs28933 were designed and obtained from Tib
molbiol (http://www.tib-molbiol.de/de/) (primer sequences are avail-
able on request). Quality assurance was achieved by the inclusion of
two CEPH controls, which were genotyped for all the SNPs in this
study, and showed a 100% concordance rate with the HapMap
genotypes (http://hapmap.ncbi.nlm.nih.gov/). Furthermore, all genotypes
were double checked by two researchers.
Statistical analyses
Quality control. All markers were tested for deviation from Hardy–
Weinberg Equilibrium (HWE), using Exact HWE as implemented in
PLINK,29 and discarded if the P-value was below 0.0001. Additionally,
markers with a call rate below 80% or a minor allele frequency (MAF)
below 0.005 were excluded from further analyses. Furthermore,
individuals with missing genotype rate above 10% were excluded
from the analyses.
Stages 1 and 2. Genotypes from the genome-wide scan and the fine
mapping of the 17q11.2-q12 region were tested for association using
Monte Carlo-based tests as implemented in CLUMP.30 The CLUMP
statistics presented in this paper are from the subtests T1 and T4. The
T1 value is the standard Pearson w2-test on the raw 2N contingency
table, and the T4 value is obtained by reshuffling the columns of the
raw 2N table into new 22 tables, until the w2-value has reached a
maximum. Significance level of 0.05 was chosen, however, to com-
pensate for the lack of correction for multiple testing, and to ensure
that the applied tests are not too conservative, thresholds of 0.005 for
single-locus analysis and 0.01 for two-locus analysis were applied.
These different thresholds were chosen mostly based on the different
number of alleles/haplotypes analysed in the single-locus and two-
locus analyses, and to prevent that tests are too conservative. Alleles
and haplotypes of markers with P-values below the threshold were,
furthermore, tested with Fisher’s exact test to detect if specific alleles
or haplotypes preferentially displayed a significant skewed distribu-
tion. IBD0 was calculated by use of the formula given by Houwen
et al.31 IBD0 indicates the probability that the given haplotype/
segment is inherited by chance with its observed frequency among
the cases, which are related to a known ancestor through a specific
genealogical relationship – the 13 cases from the genome-wide scan
share a known ancestor living 6.5 generations ago.22
Population structure analyses. Analyses of the level of relatedness and
inbreeding in the Faroese sample from stage 1 and 2 were based on
genome-wide multi locus data from 78 unlinked markers from the
genome-wide scan. Genetic differentiation among cases and controls
were evaluated by Wright’s F-statistic as implemented in SPAGEDi
1.2,32 and inter- and intra-individual correlations were estimated to
evaluate any further genetic subclustering. Furthermore, Bayesian
model-based clustering as implemented in STRUCTURE,33 was
applied to infer any potential cryptic substructure. Models with and
without admixture were applied without using any prior information
on population structure (ie, disease status).
Stage 3: Amiloride-sensitive cation channel 1 (ACCN1). Allelic
association for SNPs located within ACCN1 was tested using the
Cochran–Armitage trend test for the Faroese and Danish samples. The
Cochran–Mantel–Haenszel (CMH) test was used for the combined
Danish and Faroese sample in the open-source software PLINK.29
Haplotype association was performed using a sliding window
approach of two- and three-marker haplotypes. We report the
nominal significant associations, that is, P-values below 0.05. However,
none of these SNPs would withstand Bonferroni correcting for multi-
ple testing, which would require a P-value below 0.001. Association at
the level of the whole gene or parts of the gene was assessed using
the program COMBASSOC performed with 9999 permutations.34
COMBASSOC provides a single measurement of significance by
combining the P-values from all the SNP analyses, and subsequently
by permutation testing assessing the empirical significance of the
combined P-value.
Imputation. To infer missing genotypes and increase genomic cover-
age, SNP genotypes within the chromosome 17:28 363 219–29 509 938
region around ACCN1 were imputed using MaCH 1.035 and the 1000
Genomes maps (August 2009; ftp://share.sph.umich.edu/1000genomes/
pilot1/) as reference haplotypes (CEPH population). Prior to the
imputation analysis, five A/T or G/C SNPs and seven SNPs, which
were not genotyped in the 1000 Genome project, were excluded. Thus,
the imputation analysis was performed using 38 SNPs. Imputed
markers with a squared correlation (rsq) between imputed and true
genotypes above 0.3 and a quality score above 0.9 were accepted for
further analyses. The imputed markers were subsequently analysed for
association (trend test and CMH test) using PLINK.29
RESULTS
Stage 1: The genome-wide scan
In the genome-wide scan, 460 microsatellite markers were successfully
genotyped. Several chromosomal regions (4p16.1, 17q11.2-q12 and
19p13.2) showed significant association with PD and increased
haplotype sharing among the 13 Faroese patients. The present paper
only reports the association between PD and markers on chromosome
17. Using a threshold of 0.01, we detected a significant association
between PD and a two-marker segment (D17S1294–D17S1293)
located in the q11.2-q12 region on chromosome 17 (T1:
P-value¼0.002; T4: P-value¼0.003).
Analyses of genetic relatedness and population structure
In summary, Wright’s F-statistics revealed no signs of genetic differ-
entiation between the 13 cases and 43 controls in the initial Faroese
sample. The cluster analysis found it more likely that the data
belonged to a single cluster than to multiple clusters. Average within-
and between-group kinship coefficients did not differ significantly,
indicating that the cases are not closely related to each other than they
are to the controls. In conclusion, we observed no significant strati-
fication or cryptic relatedness, and the samples might thus be
considered sub-samples with the same genetic background.
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Stage 2: The 17q11.2-q12 region
Twenty-two microsatellites and seven SNPs within 17q11.2-q12 were
successfully genotyped. The CLUMP analyses showed a significant
haplotypic association between the two-locus segment D17S1293–
D17S1842 and PD, using a threshold of 0.01 (T1: P-value¼0.007;
T4: P-value¼0.007). Fisher’s exact test confirmed an overrepresentation
of one particular haplotype (P-value¼0.003; Table 1). No significant
association was observed between the 5-HTTLPR repeat within the
promoter region of the SLC6A4 gene and PD. Single marker analysis of
SNPs within ACCN1 revealed a significant association between PD and
three SNPs, using a threshold of 0.005, P-values ranging from 0.001 to
0.003 (Table 1). The same three SNPs and an adjacent distal micro-
satellite marker D17S1540 displayed, in addition, significant associa-
tion in the two-marker analyses performed using CLUMP and using a
threshold of 0.01, P-values ranging from 0.003 to 0.0002 (Table 1). It
appears very unlikely that the observed segments in the case group are
inherited IBD by chance through the known genealogy (Table 1).
Stage 3: Amiloride-sensitive cation channel 1 (ACCN1)
A total of 50 SNPs were successfully genotyped with an average call
rate of 0.98 (one SNP was monomorphic and five SNPs failed to be
genotyped). The statistical analyses in stage 3 were performed sepa-
rately for the three samples: the Faroese case–control samples, the
Danish case–control sample and the combined sample of Danish
and Faroese cases versus Danish and Faroese controls. None of the
SNPs showed significant deviation from HWE in the three samples
of controls. One SNP (rs11868226) was excluded due to frequency test
(MAF) in the Faroese sample, whereas none were excluded in
the Danish and combined Faroese and Danish samples. Nineteen of
193 individuals (2 cases and 17 controls) in the Faroese sample, and 18
of 888 individuals (3 cases and 15 controls) in the Danish sample
were removed due to low genotyping. No significant association at the
level of the whole gene was detected in any of the three samples,
neither when including all ten exons, nor when dividing the gene into
smaller parts.
The Faroese sample. Six SNPs showed nominal significant allelic
association with PD in the trend test, P-values ranging from 0.016
to 0.044 (Table 2). Furthermore, the haplotype analysis showed
nominal significant association between PD and several haplotypes,
P-values ranging from 0.009 to 0.047 for the two-marker haplotypes,
and 0.0064 to 0.041 for the three-marker haplotypes (data not shown).
Several of the SNPs included in the significantly associated haplotypes
were furthermore allelic associated.
The Danish samples. The association analysis showed one SNP
nominally significantly allelic associated with PD (rs9915774; P-
value¼0.031) (Table 2). The haplotype analyses revealed several
two- and three-marker haplotypes nominal significantly associated
with PD, P-values ranging from 0.003 to 0.046 (data not shown).
Rs9915774 was furthermore included in the significantly associated
two- and three-marker haplotypes.
Table 1 Alleles and segments in 17q11.2-q12 showing significant association with PD (stage 2)
CLUMP Fisher´s exact test IBD by chance
Single marker Two markers
Marker Cases Controls T1 T4 Marker T1 T4 Segment Cases Controls P (P) IBD0 (P) IBD0sum
rs28936
G 15 (0.58) 22 (0.26) 0.0030 0.0030 rs28936–rs28935 0.0025 0.0028
A 11 (0.42) 62 (0.74)
rs28935
A 15 (0.58) 74 (0.86) 0.0010 0.0010 rs28935–rs62068265 0.0033 0.0033 rs28935–rs62068265 9/26 12/86 0.0410 2.5871011 5.493109
G 11 (0.42) 12 (0.14)
rs62068265
G 24 (0.92) 84 (0.98) 0.1400 0.0140 rs62068265–rs28933 0.0006 0.0002 rs62068265–rs28933 15/26 18/84 0.0011 1.2301022 2.6731019
C 2 (0.08) 2 (0.02)
rs28933
A 15 (0.58) 18 (0.21) 0.0010 0.0010 rs28933–D17S1540 0.0007 0.0008 rs28933–D17S1540 8/18 4/72 0.0002 3.5211011 5.615109
G 11 (0.42) 66 (0.79)
D17S1540
a 9 (0.35) 9 (0.11) 0.0180 0.0200
17 (0.65) 71 (0.89)
D17S1293
a 7 (0.27) 9 (0.10) 0.1480 0.1300 D17S1293–D17S1842 0.0070 0.0070 D17S1293–D17S1842 4/18 1/86 0.0030 1.179104 1.03102
19 (0.63) 77 (0.90)
D17S1842
a 16 (0.62) 60 (0.70) 0.0670 0.0590 rs28936–rs28935–rs62068265 8/20 9/76 0.0069 9.9401011 1.541108
10 (0.48) 26 (030) rs28935–rs62068265–rs28933 8/18 5/78 0.0003 3.5211011 5.501109
rs62068265–rs28933–D17S1540 8/20 4/70 0.0005 9.9401011 1.541108
Empirical CLUMP (T1 and T4 test statistics) for single- and two-marker analyses.
Fisher’s exact test for specific haplotypes/segments (alleles not shown).
IBD0sum shows the same probability summed over all 29 markers in 17q11.2-q12.
aThe allele frequency is given for the allele showing the most skewed distribution against all other alleles.
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The combined Faroese and Danish sample. Nominal significant allelic
association was observed between PD and rs9915774 (P-value¼0.007;
Table 2). The haplotype analyses revealed several two- and three-
marker haplotypes nominal significantly associated with PD, P-values
ranging from 0.006 to 0.042 (data not shown). Rs9915774 was one of
the SNPs in the significantly associated haplotypes.
Imputation
In the 1.15-Mb region around ACCN1, 3786 SNPs were imputed
using 38 SNPs, and 415 of these had an rsq above 0.3 and a
quality score above 0.9. The genotype distribution for the imputed
SNPs did not deviate significantly from HWE. In the Faroese sample,
the trend test revealed nominal significant allelic association between
PD and 69 of the imputed SNPs, including three SNPs genotyped
in this study, P-values ranging from 0.002 to 0.049 (data not
shown). Furthermore, in the Danish sample, the trend test showed
nominal allelic association between PD and 39 of the imputed
SNPs, including one of which was genotyped in this study, P-values
ranging from 0.004 to 0.038 (data not shown). No overlap of nominal
significantly associated markers was observed between the Faroese
and Danish samples. In the combined Faroese and Danish sample,
the CMH test showed nominal significant allelic association
between PD and 39 of the imputed SNPs, including one of the
SNPs genotyped in this study, P-values ranging from 0.005 to 0.045
(data not shown).
DISCUSSION
In the search for susceptibility genes for PD, we conducted a genome-
wide scan (stage 1) and a subsequent fine-scaled follow-up study
(stage 2) on PD patients and control individuals from the Faroe
Islands. The results revealed significant allelic association and
increased haplotype sharing on chromosome 17q11.2-q12, and a
possible implication of the ACCN1 gene located within this region.
In stage 3, we analysed ACCN1 for association with PD in an extended
Faroese case–control sample, using tag-SNPs. Several SNPs within this
gene were nominal associated with PD in this extended sample. With
the intention of replicating the findings in a larger outbred population,
we analysed ACCN1 for association with PD in a Danish sample. The
results revealed one significantly associated SNP. The subsequent
imputation analyses added no substantial significant association
between ACCN1 and PD in any of the samples.
An important issue in mapping susceptibility genes for common
complex disorders is whether the genetic factors are likely to be
common or rare in a population. Using an isolated population
provides increased power to our study to detect rare variants, which
increasingly are being identified for common complex disorders.36,37
Isolated populations might pose an advantage over outbreed popula-
tions in detecting rare variants,38 as only a low number of each risk
alleles is likely to be introduced into an isolated founder population.
In this way, heterogeneity will be reduced, and the LD surrounding the
risk variant will be confined to the population history of the isolate.12
Table 2 Significantly associated SNPs within ACCN1 analysed in the extended Faroese (FO) and Danish (DK) case–control samples and in the
combined sample between Faroese and Danish cases versus Faroese and Danish controls (FO+DK) (stage 3)
FO DK FO+DK
SNP Cases Controls Ptrend Cases Controls Ptrend Cases Controls P
RS8066566
A 16 (0.28) 41 (0.14) 0.016 62 (0.13) 192 (0.15) 0.245 78 (0.15) 233 (0.15) 0.805
G 42 (0.72) 245 (0.86) 414 (0.87) 1066 (0.85) 456 (0.85) 1311 (0.85)
RS16589
A 10 (0.17) 93 (0.32) 0.020 164 (0.34) 434 (0.34) 0.895 174 (0.32) 527 (0.34) 0.392
G 48 (0.83) 195 (0.68) 316 (0.66) 824 (0.66) 364 (0.68) 1019 (0.66)
RS16585
G 2 (0.03) 45 (0.16) 0.016 47 (0.10) 145 (0.12) 0.297 49 (0.09) 190 (0.12) 0.072
A 56 (0.97) 245 (0.84) 433 (0.90) 1115 (0.88) 489 (0.91) 1360 (0.88)
RS12451625
A 1 (0.02) 28 (0.10) 0.044 37 (0.08) 102 (0.08) 0.784 38 (0.07) 130 (0.08) 0.354
G 57 (0.98) 262 (0.90) 443 (0.92) 1158 (0.92) 500 (0.93) 1420 (0.92)
RS4289044
G 17 (0.29) 47 (0.16) 0.026 116 (0.24) 278 (0.22) 0.346 133 (0.25) 325 (0.21) 0.094
C 41 (0.71) 243 (0.84) 362 (0.76) 980 (0.78) 403 (0.75) 1223 (0.79)
RS8070997
G 7 (0.12) 12 (0.04) 0.018 78 (0.16) 175 (0.14) 0.229 85 (0.16) 187 (0.12) 0.069
A 51 (0.88) 278 (0.96) 402 (0.84) 1085 (0.86) 453 (0.84) 1363 (0.88)
RS9915774
A 5 (0.09) 53 (0.19) 0.072 58 (0.12) 204 (0.16) 0.033 63 (0.12) 257 (0.17) 0.006
G 53 (0.91) 233 (0.81) 422 (0.88) 1054 (0.84) 475 (0.88) 1287 (0.83)
The allele counts are given in numbers and the frequencies are shown in brackets.
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Therefore, rare risk variants identified in isolated populations might
not necessarily explain the susceptibility of a disorder or be useful as
diagnostic markers in outbred populations. However, they could
provide important clues about the mechanism underlying a disorder
and thereby contribute to the understanding of the etiology of a
disorder like PD. In contrast, isolated populations might not be
beneficial in mapping common disease variants of low-effect size.
Common alleles would not necessarily be enriched in the isolated
population, as multiple founders most likely have introduced the same
risk allele into the founder population.39,40
The results of this study should be interpreted in the context
of several potential limitations. First, we did not correct for
multiple testing in stage 1 and 2 using standardised methods. The
Bonferroni correction, which assumes independence between
the individual tests, was considered too conservative. As many of
the markers are in close proximity, they are likely in LD,41 and the
association tests performed are hence not independent. However, to
compensate for multiple testing and reduce the type I error rate,
we applied relatively low thresholds in stage 1 and 2. Furthermore,
the combined approach with association analysis and IBD
estimates should reduce the number of stochastic single-point obser-
vations. In stage 3, no correction for multiple testing was performed,
and therefore, the nominal-associated observations might represent
false positives.
Second, even though we used an isolated population, which may
justify the small sample size in the Faroese sample, we cannot ignore
that this may affect the P-values and the power to detect true
difference in allele frequencies between cases and controls. Third,
most of the association was confined to the Faroese sample, which
might suggest that possible risk alleles genotyped in the present study
are not necessarily those involved in the development of PD in a larger
outbred population. However, it is possible that low number of
founders, isolation and genetic drift followed by rapid exponential
population growth has rendered the Faroese population homogenous
enough to be able to detect possible risk alleles not detectable in the
larger outbred population. To confirm or reject the trend for associa-
tion observed between markers located within ACCN1 and PD, it
might be of interest to analyse Norwegian and Scottish/Irish case–
control samples, as these populations most likely contributed much
more to the founding of the Faroese population than the Danish.14,15
Fourth, we did not consider the possible population stratification in
the extended Faroese sample and the Danish sample. However, we
detected no significant stratification between cases and controls in the
initial Faroese sample, which might apply to the extended Faroese
sample as well, considering the assumed reduced-genetic heterogeneity
in isolated populations.41 But, we should not ignore that even
apparently homogeneous and isolated populations may have levels
of population stratification.42 Fifth, we excluded the large intron
comprising 1 Mb of the gene, and have therefore not described all
the genetic variation within ACCN1. Using the 50 tag-SNPs success-
fully genotyped in this study, we were able to describe the genetic
variation of 120 SNPs. We find this strategy sensible, as 500 tag-SNPs
would be required to capture all the genetic variation. The 17q11.2-
q12 region, comprising a deletion, which recently has been associated
with autism spectrum disorder and schizophrenia,43 contains other
interesting candidate genes, one of which is myosin 1D (MYO1D)
previously associated with major autism.44 Furthermore, two trans-
membrane proteins – transmembrane protein 98 (TMEM98) and
transmembrane protein 132E (TMEM132E; see Figure 1) – are located
in close proximity to ACCN1. Recent studies have shown a possible
role of transmembrane gene 132D (TMEM132D) in the etiology of
PD.45,46 It might, therefore, be relevant to analyse these genes in future
studies of PD.
In summary, we observed nominal association between PD and
SNPs within the ACCN1 gene, yet it is unlikely from our data that
ACCN1 has a major role in the general genetic susceptibility of PD. We
can therefore not confirm the involvement of ASICs in triggering
panic attacks. This is consistent with the inconclusive results from
association analysis between anxiety spectrum disorders and
ACCN2.47 It is still unknown whether there are susceptibility genes
with major effects in the etiology of PD; therefore, ACCN1 might be
one of numerous susceptibility genes for PD, each contributing a
moderate effect. Furthermore, most of the association was confined to
the Faroese sample, which might be due to the different population
history of the study populations. Thus, it might be of interest to
analyse ACCN1 in Norwegian and Scottish/Irish case–control samples.
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